Form 4: Corcept Therapeutics Officer Lyon Exercises Options and Sells Shares
SEC Form 4 Filing
Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on March 24, 2025, according to a recent SEC filing.
Summary
- On March 24, 2025, Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options to acquire 421 shares of common stock at a price of $13.56 per share.
- Simultaneously, Lyon sold 421 shares of Corcept Therapeutics common stock at a price of $60.58 per share.
- Following these transactions, Lyon directly owns 9,009 shares of Corcept Therapeutics common stock and holds options for 91,571 shares.
- The sale was conducted under a pre-arranged 10b5-1 trading plan adopted on August 30, 2024.
Sentiment
Score: 5
Explanation: Neutral sentiment as it reports routine stock transactions by an officer. The transactions appear to be part of a pre-planned strategy (10b5-1 plan) and do not necessarily indicate a change in the officer's confidence in the company.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects. The use of 10b5-1 plans is a standard practice to avoid accusations of insider trading.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock awards to align management's interests with those of shareholders.
- The use of 10b5-1 trading plans is a widespread practice among corporate executives to manage their stock transactions in compliance with insider trading regulations.
- Comparing Lyon's transactions to those of executives at similar-sized pharmaceutical companies like Exelixis or Incyte could provide a benchmark for assessing the magnitude and frequency of insider trading activity.
Key Dates
| Date | Description |
|---|---|
| 08/30/2024 | Date of adoption of 10b5-1 trading plan |
| 03/03/2025 | Date of grant of restricted stock awards |
| 03/24/2025 | Date of transaction (exercise of options and sale of shares) |
| 03/26/2025 | Date of signature on the Form 4 filing |
| 02/07/2030 | Expiration date of stock options |
Keywords
Form 4, SEC Filing, Corcept Therapeutics, CORT, Joseph Douglas Lyon, Stock Options, Share Sale, 10b5-1 Plan, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.